CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
© The Author(s). 2016
Received: 20 April 2016
Accepted: 5 September 2016
Published: 9 September 2016
Ovarian cancer (OC) ascites consist in a proinflammatory tumor environment that is characterized by the presence of various cytokines, chemokines and growth factors. The presence of these inflammatory-related factors in ascites is associated with a more aggressive tumor phenotype. CCL18 is a member of CCL chemokines and its expression has been associated with poor prognosis in some cancers. However, its role in OC progression has not been established. Therefore, the aim of the current study was to elucidate the role of ascites CCL18 in OC progression.
ELISA and tissue microarrays were used to assess CCL18 in ascites and phospho-Pyk2 expression in cancer tissues respectively. Cell migration was assessed using Boyden chambers. CCL18 and ascites signaling was examined in ovarian cancer cells utilizing siRNA and exogenous gene expression.
Here, we show that CCL18 levels are markedly increased in advanced serous OC ascites relative to peritoneal effusions from women with benign conditions. Ascites and CCL18 dose-dependently enhanced the migration of OC cell lines CaOV3 and OVCAR3. CCL18 levels in ascites positively correlated with the ability of ascites to promote cell migration. CCL18 blocking antibodies significantly attenuated ascites-induced cell migration. Ascites and CCL18 stimulated the phosphorylation of proline-rich tyrosine kinase 2 (Pyk2) in CaOV3 and OVCAR3 cells. Most importantly, the expression of phosphorylated Pyk2 in serous OC tumors was associated with shorter progression-free survival. Furthermore, enforced expression of Pyk2 promoted tumor cell migration while siRNA-mediated downregulation of Pyk2 attenuated cell migration. Downregulation of Pyk2 markedly inhibited ascites and CCL18-induced cell migration.
Taken together, our findings establish an important role for CCL18, as a component of ascites, in the migration of tumor cells and identify Pyk2 as prognostic factor and a critical downstream signaling pathway for ascites-induced OC cell migration.
KeywordsPyk2 Ovarian carcinoma Ascites CCL18 Cell migration
Ovarian cancer (OC) is the second most frequent gynecological cancer and is associated with a poor prognosis because OC progression is often asymptomatic and is detected at a late stage. Widespread intraperitoneal metastasis is the major cause of mortality among OC patients [1, 2]. It results from a sequential process in which tumor cells shed from the primary tumor into ascites are disseminated throughout the peritoneal cavity [1, 2]. Most OC patients present with advanced diseases (stage III/IV) with large amount of ascites. The presence of ascites at diagnostic correlates with peritoneal spread of the tumor and with a decreased 5-year survival rate [3–5]. A variety of cytokines, chemokines and growth factors are present in OC ascites [6–8]. There is growing evidence that inflammatory cytokines/chemokines within ascites lead to a state of chronic inflammation [9, 10]. Chronic inflammation, in turn, contributes to tumor progression by creating a proliferative, migrating and prosurvival environment [11, 12]. Indeed, OC ascites have been shown to enhance tumor cell proliferation, migration and survival [13–17].
Chemokines are important components of cancer-related inflammation and, in the tumor environment, may play a pivotal role in tumor progression and metastasis. Chemokine (C-C motif) ligand 18 (CCL18), which is predominately produced by tumor-associated macrophages (TAMs), promote the migration and invasion of breast cancer cells [18, 19]. CCL18 also correlates with metastasis and poor prognosis of patients with breast cancer . CCL18 is expressed at higher levels in OC ascites compared to none ovarian carcinomas . Its tissue expression correlates with metastasis in OC patients . Serum levels of CCL18 has been examined as a potential biomarker for discriminating patients with OC versus those with benign gynecological conditions .
CCL18 effects on migration and invasion of breast cancer cells are mediated by the proline-rich tyrosine kinase 2 (Pyk2) . Pyk2 is a cytoplasmic tyrosine kinase that belongs to the focal adhesion kinase (FAK) family . CCL18 specifically binds PITPNM3/Nir1 receptor and activates Pyk2 by phosphorylation of tyrosine residue Y402 that functions as a docking site for the SH2 domain of Src . Pyk2 regulates different signal transduction cascade that control cell proliferation, migration and invasion [20, 22, 26, 27]. Pyk2 is overexpressed in hepatocellular carcinoma (HCC) cells and its expression is associated with poor prognosis . Enforced expression of Pyk2 promotes migration and invasion in HCC cells via the activation of ERK pathway [27, 28]. Little is known however about the role Pyk2 in OC cells.
In this study, we aim to investigate the contribution of the tumor environment to CCL18/Pyk2 signaling and the migration of OC cells. We demonstrate that high levels of CCL18 are present in OC ascites and that CCL18 is an important component of ascites for the ascites-mediated migration of OC cells. Ascites and CCL18 stimulate the phosphorylation and expression of Pyk2, which is critical for mediated CCL18-induced migration.
Ascites are routinely obtained at the time of the debulking surgery of ovarian cancer patients treated at the Centre Hospitalier Universitaire de Sherbrooke. After collection, cell-free ascites are stored at −80 °C in our tumor bank until use. The study population consisted of 53 women with newly diagnosed epithelial ovarian cancer admitted at the Centre Hospitalier Universitaire de Sherbrooke. Twenty four cases with histologically benign gynecological conditions including fibromas, endometriosis, and mucinous and serous cystadenomas constituted the control group. This study was approved by the Institutional Review Board of the Centre de Recherche Étienne-Le Bel. Informed consent was obtained from women that underwent surgery by the gynecologic oncology service between 2000 and 2014. All samples were reviewed by an experienced pathologist. Baseline characteristics and serum CA125 levels were collected for all patients. All patients had a follow up ≥12 months. Disease progression was defined by either serum CA125 ≥2 X nadir value on two occasions, documentation of lesion progression or appearance of new lesions on CT-scan or death. Patient’s conditions were staged according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO). PFS was defined by the time from the initial surgery to evidence of disease progression.
Cell culture and reagents
The human OC cell lines CaOV3 and OVCAR3 were obtained from the American Type Culture Collection (Manassas, VA) and maintained in a humidified 5 % CO2 incubator at 37 °C. Cells were passaged twice weekly. OVCAR3 cells were maintained in RPMI-1640 (Wisent, St-Bruno, QC, Canada) supplemented with 20 % FBS, insulin (10 mg/L), glutamine (2 mM) and antibiotics. CaOV3 cells were cultured in DMEM/F12 (Wisent) supplemented with 10 % FBS, 2 mM glutamine and antibiotics. Acellular ascites fractions were obtained at the time of initial cytoreductive surgery from women with advanced serous ovarian carcinomas. Samples were supplied by the Banque de tissus et de données cliniques et biologiques sur les cancers gynécologiques et du sein de Sherbrooke as part of the Banque de tissus et de données du Réseau de Recherche en Cancer des Fonds de Recherche du Québec en Santé (FRQS) affiliated to the Canadian Tumor Repository Network (CTRNet). HRP-conjugated anti-mouse and rabbit antibodies and anti-FAK antibody were purchased from Cell Signaling Technology (Danvers, MA). Anti-phospho FAK and anti-phospho Pyl2 were from Thermo Fisher (Waltham, MA). Anti-Pyk2 and anti-Tubulin were purchased from Sigma-Aldrich (Oakville, ON). CCL18 and CCL18 neutralizing antibody were from RnD Systems (Minneapolis, MN). Plasmid pCMV6-ENTRY-PTK2B was obtained from Origene (Rockville, MD).
Quantitative real time PCR
Total RNA was extracted from CaOV3 cells using TRIzol reagent (Life Technologies) according to the manufacturer’s protocol and subjected to reverse transcription (RT) with oligodT from Promega (Madison, WI) and MMULV reverse transcriptase enzyme. RNA concentrations were quantified by measurement of absorbance at 260 nm. The integrity of the cDNA was assessed with the Taqman gene expression assays (Life Technologies), done on RPLPO housekeeping gene. Each sample was normalized to the housekeeping gene levels. Primers for Pyk2 are as follow: Forward: 5′-CGGACTGATGACCTGGTGTA-3′, Reversed: 5′-TTCTTCACCACCACCACGTA-3′. Cycle conditions for all PCRs were as follow: an initial incubation of 2 min at 95 °C followed by 35 cycles at 94 °C 30 s, 55 °C 30 s, 72 °C 60 s. The 2-ΔΔCt method was used to calculate the relative levels of specific mRNA.
Cells (5 × 103) were suspended in 500 μl FBS and hormone-free DMEM/F12 and were seeded in the top chamber of monolayer-coated polyethylene terephthalate membranes cell culture inserts (24-wells insert, 8 μm pore size). The bottom chamber contained 0.75 ml DMEM/F12 supplemented with 10 % fetal bovine serum, 10 % ascites, or CCL18. The cells were incubated for 16–20 h, and cells that did not migrate through the membrane were removed by scraping with a cotton swab. Cells that migrated through the membrane were fixed with ice cold methanol for 10 min and stained with a 0.5 % crystal violet, 20 % (v/v) hematoxylin solution in ethanol for 15 min. After several washes in PBS, membranes were allowed to dry before being mounted on a glass slide. Ten random fields were counted at × 100 magnification.
Cytokine levels in peritoneal fluid samples were determined by ELISA using the commercially available human Quantikine kits from R&D Systems (Minneapolis, MN). The assays were performed in duplicate according to the manufacturer’s protocols. The detection threshold was 1.1 ng/ml for CCL18. The intra-assay variability was 3.2–3.7 % for CCL18. The inter-assay variability was 3.5 %. All samples were examined in duplicate and the median values were used for statistical analysis.
Western blot analysis
Cells were harvested and washed with ice-cold PBS. Whole cell extracts were prepared in lysing buffer (glycerol 10 %, Triton X-100 1 %, TRIS 10 mM pH 7.4, NaCl 100 mM, EGTA 1 mM, EDTA 1 mM, SDS 0.1 %) containing protease inhibitors (0.1 mM AEBSF, 5 μg/ml pepstatin, 0.5 μg/ml leupeptin and 2 μg/ml aprotinin) and phosphatase inhibitors (Na4P2O7 20 mM, NaF 1 mM, Na3VO4 2 mM). Proteins were separated by 12 % SDS-PAGE gels. Proteins were transferred to PVDF membranes (Roche, Laval, Québec, Canada) by electroblotting, and immunoblot analysis was performed as previously described . All primary antibodies were incubated overnight at 4 °C in 5 % fat-free milk. Proteins were visualized by enhanced chemiluminescence (GE Healthcare, Baie d’Urfé, Québec, Canada).
The Fluorescein-labeled Luciferase GL2 duplex or a non-target (scrambled) siRNAs used as a control were from Dharmacon Research (Lafayette, CO). Cells (6 × 104) were seeded in 6-well plates and allowed to adhere for 24 h. Cells (50 % confluent) were transfected with a mixture containing Lipofectamine 2000™ (Life Technologies), optiMEM (Life Technologies) and siRNA (10 μM). The siRNAs/Lipofectamine complex was then added to the media of 6-well plates containing cells. Cells were incubated for 4–6 h at 37 °C in a CO2 incubator and medium containing FBS was then added. The Pyk2 smart pool siRNAs was from GE Health Care (Ottawa, Canada).
TMAs were acquired from the Pan-canadian platform for the development of biomarker-driven subtype specific management of ovarian carcinoma (COEUR study). Slides were deparaffinized in citrate buffer containing 0.05 % Tween at 97 °C for 20 min, washed with PBS and incubated with 3 % peroxide. After treatment, slides were submerged in a citrate buffer (0.01 M citric acid, pH 6.0) for 15 min, and incubated with a protein blocking serum-free reagent (Dako Canada). The TMAs were stained by an immunoperoxidase method using an automated tissue immunostainer (Dako Canada) with DABchromogen. The TMAs were counter stained with hematoxilin and slides were scanned using HAMAMATSU Nanozoomer (Boston, MA) and each tissue section were scored according to the staining intensity where negative staining = 0, low staining = 1+, moderate staining = 2+ and high staining = 3+. Two separate TMAs containing different section of the same tumor were scored and the mean intensity was used.
Statistical comparisons between two groups were performed using the Mann-Whitney or Student’s t-test. The correlation between phospho-FAK and phospho-Pyk2 expression in tissue section was determined by the Pearson’s correlation test. Statistical differences in PFS or overall survival were determined by the log-rank test, and Kaplan-Meier survival curves were made. PFS was defined as the interval between the date of the initial debulking surgery and the time of disease progression or the last date of follow up. Statistical significance was indicated by P < 0.05.
Levels of CCL18 in malignant ascites from ovarian cancer patients
We next correlated the levels of CCL18 in ascites with the progression-free survival (PFS). Women were separated in CCL18 high and low groups based on the CCL18 median level in ascites. A Kaplan-Meier progression-free survival curve showed that, although it did not reach statistical significance, women with low CCL18 (<21.4 ng/ml) had a tendency for longer PFS with a median of 21 months compared to 18 months for those with high CCL18 (>21.7 ng/ml) level in ascites (log rank test, P = 0.31) (Fig. 1b).
Malignant ascites and CCL18 stimulate the migration of ovarian cancer cells
To further define the role of CCL18 in ascites-induced cell migration, we examined the effect of a CCL18-blocking antibody. As shown in Fig. 2f, the ascites-induced migration of OC cells was significantly inhibited by the preincubation of ascites with the CCL18-blocking antibody. Although significant, the CCL18-blocking antibody only achieved a partial (43 to 57 %) inhibition of ascites-induced migration suggesting the possible contribution of other factors in this process. Nonetheless, our data suggest that CCL18 is an important factor in ascites that promotes the migration of OC cells. The difference in the magnitude of ascites-induced effect on migration between CaOV3 and OVCAR3 cells was not related the CCL18 receptor expression as PITPNM3 levels were found to be similar in both cell lines (Fig. 2g).
Ascites and CCL18 induce activation of Pyk2 in ovarian cancer cells
Pyk2 activation in advanced serous ovarian cancer
We next examined the correlation of pPyk2 expression with progression-free survival and overall survival. Women with pPyk2 positive tumors had a significantly shorter progression-free survival than women with pPyk2 negative tumors (Fig. 4b). The median progression-free survival of women with pPyk2 positive tumors was 16 months compared to >80 months for women with pPyk2 negative tumors (Log-rank test, P = 0.032). We observed a tendency towards decreased overall survival in women with pPyk2 positive tumors with a median overall survival of 46 months compared to 59 months for women with pPyk2 negative tumors (Log-rank test, P = 0.087) (Fig. 4b).
Pyk2 positively regulates ascites-induced ovarian cancer cell migration
Pyk2 downregulation inhibits CCL18 and ascites-induced cell migration
To confirm the involvement of CCL18 in the induction of OC cell migration, we examined whether the downregulation of Pyk2 could block CCL18-induced migration. As shown in Fig. 6c, the CCL18-induced effect was significantly inhibited by siRNA-mediated attenuation of Pyk2 protein expression in both CaOV3 and OVCAR3 cells. These results suggest that CCL18 in ascites may participate in the induction of migration.
Ovarian cancer is a highly metastatic disease characterized by widespread intraperitoneal dissemination and ascites formation. Cancer-related inflammation plays an important role in OC progression . Chemokine production is associated with chronic inflammation and high levels are found in ascites from advanced OC . Some inflammation-related factors in ascites have been shown to play a pivotal role in pancreatic cancer progression and metastasis . In the present study, we show that CCL18, a C-C chemokine mainly secreted by monocyte-derived cells with M2 phenotype , was present at significantly higher levels in ascites obtained from women with advanced serous OC compared to women with benign gynecological conditions. This is consistent with previous data showing high levels of CCL18 in ovarian cancer patients [21, 22]. Although women with high levels of CCL18 had generally a worse outcome compared to women with low CCL18 in our study, the difference did not reach statistical significance. This is perhaps not surprising given the complex nature of OC ascites and the overall outcome is most likely the results of the combined effect of each individual factors affecting tumor cell behavior.
Unlike most carcinomas, OC dissemination is primarily mediated by the shedding of tumor cells from the primary site into peritoneal fluids where they formed free-floating multicellular spheroids that rapidly lead to peritoneal carcinomatosis . Development of pelvic and peritoneal metastasis involves well-defined critical steps, including cell exfoliation, resistance to apoptosis, interaction and adhesion to mesothelial layer, migration and proliferation [36, 37]. We previously demonstrated that OC ascites protect tumor cells from apoptosis through activation of Akt and Erk signaling resulting in the upregulation of anti-apoptotic proteins Mcl-1 and cFLIP [13–15]. This study provide the first evidence that CCL18 in ascites is a factor involved in the stimulation of tumor cell migration. In accordance with this, we found a positive correlation between the levels of CCL18 in ascites and its ability to enhance cell migration, and blocking CCL18 antibodies can inhibit ascites-induced cell migration. The mechanisms of CCL18 action include a direct effect on tumor cells via the activation of Pyk2. This is supported by the following observations. First, siRNA-mediated downregulation of Pyk2 protein expression inhibited the migration response to ascites as well as CCL18-induced migration. Second, the CCL18 levels in ascites were high enough to stimulate the migration of tumor cells and to activate Pyk2. Third, enforced expression of Pyk2 in OC cells markedly enhanced their migration. Finally, siRNA-mediated downregulation of Pyk2 protein significantly attenuated OC cell migration.
In the current study, we demonstrated for the first time that Pyk2 activation in high-grade serous OC was significantly associated with decreased progression-free survival but not with overall survival. In our tissue microarray analysis of 84 clinical samples derived from patients with advanced serous ovarian cancer, women with pPyk2 positive tumors had a 16 months median progression-free survival compared to >80 months for women with pPyk2 negative tumors. This is consistent with previous studies demonstrating an association between Pyk2 expression and worse outcome in hepatocellular carcinomas [38, 39]. Expression of pPyk2 was found in nearly 80 % of advanced serous ovarian cancer patients. It is well established that epithelial-to-mesenchymal (EMT)-associated processes, including cell migration, are determinants for metastasis and therefore poor prognosis. Pyk2 has been reported to induce EMT . Hence, our findings suggest that Pyk2 could enhance EMT and contribute to ovarian cancer progression and metastasis resulting in a worse outcome. Pyk2 integrates ascites signaling to potentiate cell migration. Specifically, we found that Pyk2 is activated by CCL18 in a dose-dependent manner and its depletion leads to substantial inhibition of ascites and CCL18-mediated cell migration. However, CCL18 may not be the only factor in ascites capable of activating Pyk2. Epidermal growht factor (EGF), HER2 and IL-8 receptors have also been shown to activate Pyk2 . These factors have been found to be present in ascites and Pyk2 may therefore integrate signaling from various factors in ascites. This could explain why the levels of CCL18 alone in ascites were not correlated with progression-free survival whereas pPyk2 expression was associated with shorter progression-free survival. Although this would deserve further studies, pPyk2 could represent a new OC prognostic biomarker.
The present study suggests the importance of CCL18 in ascites-mediated cell migration, but this finding does not rule out the possible involvement of other factors from ascites in tumor cell migration. For example, fibronectin, lysophosphatidic acid (LPA), IL-6 and CCL2 have all been shown to enhance OC migration and these factors may be present at high level in ascites [42–45]. The fact that Pyk2 downregulation only partially abrogate ascites-mediated cell migration is in line with this possibiliy and raises the possibility that other factors in ascites can signal through other signaling pathways to stimulate cell migration. It is also possible that CCL18 may affect cell migration through Pyk2-independent signaling pathways. For example CCL18 has been shown to promote metastasis via mTOR and ERK1/2-NF-kB signaling pathways [22, 46].
In this study, we investigated the contribution of the tumor environment in tumor cell migration. CCL18 was identified as one of the soluble factors responsible for ascites-induced ovarian cancer cell migration through activation of Pyk2. Pyk2 activation was clinically associated with shorter progression-free survival in women with advanced ovarian cancer. Therefore, CCL18 and pPyk2 may represent potential therapeutic targets for OC women.
We are grateful to the Banque de tissus et données of the Réseau de recherche sur le cancer of the Fond de recherche du Québec en Santé (FRQS), associated with the Canadian Tumor Repository Network (CTRNet), for providing malignant ascites and peritoneal fluids.
This work was supported by funds from the Canadian Institute for Health Research (MOP-244194-CPT-CFDA-48852), the Centre de Recherche Clinique Étienne-Lebel du Centre Hospitalier Universitaire de Sherbrooke and the Université de Sherbrooke. Tumor banking was supported by the Banque de tissus et données of the Réseau de recherche sur le cancer of the Fond de recherche du Québec en Santé (FRQS), associated with the Canadian Tumor Repository Network (CTRNet).
Availability of data and materials
AP and CR contributed to the conception and design and interpretation of the data. AP drafted the manuscript. DL performed the CCL18 measurements, most of the immunoblots and the cell migration assays. IM performed the analysis of the tissue microarray data, some of the cell migration assays and provided the ascites for this study. AC contributed to analysis of the statistical data. CL and PGG review the pathological data. PB provided the samples for tissue banking. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
This study was conducted in compliance with the Quebec legislation and the declaration of Helsinki regarding ethical principles for medical research involving human subjects. This study was approved by the Institutional Review Board of the Centre de Recherche Clnique du Centre Hospitalier Universitaire de Sherbrooke. Informed consent was obtained from women that underwent surgery by the gynecologic oncology service between 2000 and 2014. The ethic approval for this study has been included as a Additional file 1.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415–28.View ArticlePubMedPubMed CentralGoogle Scholar
- Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5:19–24.View ArticlePubMedGoogle Scholar
- Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 2002;87:77–83.View ArticlePubMedGoogle Scholar
- Ayhan A, Gultekin M, Taskiran C, Dursun P, Firat P, Bozdag G, Celik NY, Yuce K. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer. 2007;17:68–75.View ArticlePubMedGoogle Scholar
- Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18:945–9.View ArticlePubMedGoogle Scholar
- Matte I, Lane D, Laplante C, Rancourt C, Piché A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res. 2012;2:566–80.PubMedPubMed CentralGoogle Scholar
- Lane D, Matte I, Rancourt C, Piché A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11:210.View ArticlePubMedPubMed CentralGoogle Scholar
- Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009;29:2875–84.PubMedGoogle Scholar
- Maccio A, Madeddu C. Inflammation and ovarian cancer. Cytokine. 2012;58:133–47.View ArticlePubMedGoogle Scholar
- Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine. 2008;43:374–9.View ArticlePubMedGoogle Scholar
- Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.View ArticlePubMedGoogle Scholar
- Lane D, Robert V, Grondin R, Rancourt C, Piché A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt in human ovarian carcinoma cells. Int J Cancer. 2007;121:1227–37.View ArticlePubMedGoogle Scholar
- Lane D, Goncharenko-Khaider N, Rancourt C, Piché A. Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene. 2010;29:3519–31.View ArticlePubMedGoogle Scholar
- Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer. 2012;11:84.View ArticlePubMedPubMed CentralGoogle Scholar
- Puiffe M-L, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson A-M. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia. 2007;9:820–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Matte I, Lane D, Laplante C, Garde-Granger P, Rancourt C, Piché A. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and –independent mechanisms. Int J Cancer. 2015;137:289–98.View ArticlePubMedGoogle Scholar
- Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L, Yao H, Su F, Anderson KS, Liu Q, Ewen ME, Yao X, Song E. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011;19:541–55.View ArticlePubMedPubMed CentralGoogle Scholar
- Li HY, Cui XY, Wu W, Yu FY, Yao HR, Liu Q, Song EW, Chen JQ. Pyk2 and Scr mediate signaling to CCL18-induced breast cancer metastasis. J Cell Biochem. 2014;115:596–603.View ArticlePubMedGoogle Scholar
- Zhang B, Yin C, Li H, Shi L, Liu N, Sun Y, Lu S, Liu Y, Sun L, Li X, Chen W, Qi Y. Nir1 promotes invasion of breast cancer cells by binding to chemokine (C-C motif) ligand 18 through the PI3K/Akt/GSK-3β/Snail signaling pathway. Eur J Cancer. 2013;49:3900–13.View ArticlePubMedGoogle Scholar
- Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/Pulmonary and Activation-regulated chemokine in ovarian carcinoma. J Biol Chem. 2002;277:24584–93.View ArticlePubMedGoogle Scholar
- Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi M, Zhang W, Li D, Li L. CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 2015;9999:1–12.Google Scholar
- Zohny SF, Fayed ST. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol. 2010;27:1246–53.View ArticlePubMedGoogle Scholar
- Lipinski CA, Loftus JC. Targeting Pyk2 for therapeutic intervention. Expert Opin Ther Targets. 2010;14:95–108.View ArticlePubMedPubMed CentralGoogle Scholar
- Lev S, Hernandez J, Martinez R, Chen A, Plowman G, Schlessinger J. Identification of a novel family of targets of PYK2 related to Drosophila retinal degeneration B (rdgB) protein. Mol Cell Biol. 1999;19:2278–88.View ArticlePubMedPubMed CentralGoogle Scholar
- Okigaki M, Davis C, Falasca M, Harroch S, Felsenfeld DP, Sheetz MP, Schlessinger J. Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proc Natl Acad Sci U S A. 2003;100:10740–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng Q, Lo CM, Poon RT, Fan ST. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Carcinogenesis. 2008;29:2096–105.View ArticlePubMedGoogle Scholar
- Sun CK, Ng KT, Lim ZX, Cheng Q, Lo CM, Poon RT, Man K, Wong N, Fan ST. Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition. PLoS One. 2011;6:e18878.View ArticlePubMedPubMed CentralGoogle Scholar
- Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF. Characterization of a human ovarian carcinoma cells line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983;43:5379–89.PubMedGoogle Scholar
- Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000;2:249–56.View ArticlePubMedGoogle Scholar
- Sasaki H, Nagura K, Ishino M, Tobioka H, Kotani K, Sasaki T. Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem. 1995;270:21206–19.View ArticlePubMedGoogle Scholar
- Lim ST, Miller NL, Nam JO, Chen XL, Lim Y, Schlaepfer DD. Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival. J Biol Chem. 2010;285:1743–53.View ArticlePubMedGoogle Scholar
- Zhao H, Liu X, Zou H, Dai N, Yao L, Zhang X, Gao Q, Liu W, Gu J, Yuan Y, Bian J, Liu Z. Osteoprotegerin disrupts peripheral adhesive structures of osteoclasts by modulating Pyk2 and Src activities. Cell Adh Mig. 2016;8:1–11.Google Scholar
- Matsuo Y, Takeyama H, Guha S. Cytokine network: new targeted for pancreatic cancer. Curr Pharm Des. 2012;18:2416–9.View ArticlePubMedGoogle Scholar
- Kodelja V, Muller C, Politz O, Hakji N, Orfanos CE, Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol. 1998;160:1411–8.PubMedGoogle Scholar
- Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol. 2009;113:143–8.View ArticlePubMedGoogle Scholar
- Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer. 2003;2:14.View ArticlePubMedPubMed CentralGoogle Scholar
- Sun CK, Ng KT, Sun BS, Ho JW, Lee TK, Ng I, Poon RT, Lo CM, Liu CL, Man K, Fan ST. The significance of proline-rich tyrosine kinase 2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br J Cancer. 2007;97:50–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Cao J, Chen Y, Fu J, Qian YW, Ren YB, Su B, Luo T, Dai RY, Huang L, Yan JJ, Wu MC, Yan YA, Wang HY. High expression of proline-rich tyrosine kinase 2 is associated with poor survival of hepatocellular carcinoma via regulating phosphatidylinositol 3-kinase/AKT pathway. Ann Surg Oncol. 2013;20:s312–323.View ArticlePubMedGoogle Scholar
- Verma N, Keinan O, Selitrennik M, Karn T, Filipits M, Lev S. Pyk2 sustains endosomal-derived receptor signaling and enhances epithelial-to-mesenchymal transition. Nat Commun. 2015;6:6064.View ArticlePubMedGoogle Scholar
- Selitrennik M, Lev S. Pyk2 integrates growth factor and cytokine receptors signaling and potentiates breast cancer invasion via a positive feedback loop. Oncotarget. 2015;6:22214–26.View ArticlePubMedPubMed CentralGoogle Scholar
- Yousif NG. Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway. Cell Biol Int. 2014;38:85–91.View ArticlePubMedGoogle Scholar
- Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, Sun P, Huang S. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res. 2004;64:4209–17.View ArticlePubMedGoogle Scholar
- Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML, Wei LH. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011;71:424–34.View ArticlePubMedGoogle Scholar
- Furukama S, Soeda S, Kiko Y, Suzuki O, Hashimoto Y, Watanabe T, Nishiyama H, Tasaki K, Hojo H, Abe M, Fujimori K. MCP-1 promotes invasion and adhesion of human ovarian cancer cells. Anticancer Res. 2013;33:4785–90.Google Scholar
- Hou X, Zhang Y, Qiao H. CCL18 promotes the invasion and migration of gastric cancer cells via ERK1/2/NF-kB signaling pathway. Tumor Biol. 2015. doi:https://doi.org/10.1007/s13277-015-3825-0.Google Scholar